Cell-Bound Complement Activation Products (CB-CAPs) as a Source of Lupus Biomarkers
Measurement of serum C3 and C4 has been used for several decades to monitor disease activity in patients with SLE. Despite the limited utility and recognized weaknesses of these assays, they have remained the gold standard during an era of unprecedented discovery in the complement field. The current urgent need for lupus biomarkers warrants efforts to mine the complement system for assays superior to serum C3 and C4. Recent studies of soluble and cell-bound complement activation products hold promise for achieving this goal.
KeywordsSystemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Complement Activation Monitor Disease Activity Inactive Systemic Lupus Erythematosus
Unable to display preview. Download preview PDF.
- 1.C. Hohan, S.K. Datta, Lupus. Key pathogenic mechanisms and contributing factors, Clin Immunol Immunopathol 77:209–220 (1996).Google Scholar
- 4.J.S. Navratil, J.M. Ahearn, Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus, Curr Rheumatol Rep 2:32–38 (2001).Google Scholar
- 13.D.M. Ricker, L.A. Hebert, R. Rohde, D.D. Sedmak, E.J. Lewis, J.D. Clough, et al., Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels, Am J Kidney Dis 19:678–685 (1991).Google Scholar
- 14.L. Milis, B.A. Pussell, V. Timmermans, J.A. Charlesworth, C.A. Morris, The value of complement measurements in the assessment of lupus activity, Aust NZ J Med 22:338–344 (1992).Google Scholar
- 19.W.J.W. Morrow, D.A. Isenberg, A. Todd-Porkropek, H.F. Parry, M.L. Snaith, Useful laboratory measurements in the management of systemic lupus erythematosus, Q J Med 202:125–138 (1982).Google Scholar
- 24.H.M. Belmont, P. Hopkins, H.S. Edelson, H.B. Kaplan, R. Ludewig, G. Weissmann, et al., Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease, Arthritis Rheum 29:1085–1089 (1996).Google Scholar
- 26.Y.Y. Chiu, R.M. Nisihara, R. Wurzner, M. Kirschfink, I.J. do Messias-Reason, sC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients, J Investig Allergy Clin Immunol 8:239–244 (1998).Google Scholar
- 34.G. Sturfelt, A.G. Sjoholm, Complement components, complement activation, and acute phase response in systemic lupus erythematosus, Int Arch Allerg Appl Immunol 75:75–83 (1984).Google Scholar
- 36.L.G. Hunsicker, S. Ruddy, C.B. Carpenter, P.H. Schur, J.P. Merrill, H.J. Muller-Eberhard, et al., Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med 287:835–840 (1972).PubMedCrossRefGoogle Scholar
- 39.J.P. Atkinson, A.C. Chan, D.R. Karp, C.C. Killion, R. Brown, D. Spinella, et al., Origin of the fourth component of complement related Chido and Rodgers blood group antigens, Complement 5:65–76 (1998).Google Scholar
- 42.G.D. Ross, W.J. Yount, M.J. Walport, J.B. Winfield, C.J. Parker, C.R. Fuller, et al., Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation, J Immunol 135:2005–2014 (1985).PubMedGoogle Scholar